SCHEMBL16057516

SCHEMBL16057516

CCCCc1c(-c2ccc(C(F)(F)F)cc2)ccnc1OC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP2A P11388 1/20 0.42
▸ BACE1 P56817 1/20 0.40
▸ GPR119 Q8TDV5 2/20 0.39
▸ ACACB O00763 1/20 0.38
▸ PPARD Q03181 3/20 0.38
▸ TACR1 P25103 2/20 0.37
▸ LTB4R Q15722 1/20 0.37
▸ SLC22A12 Q96S37 1/20 0.37
▸ PTGDR2 Q9Y5Y4 3/20 0.36
▸ PSEN1 P49768 1/20 0.36
▸ PSEN2 P49810 1/20 0.36
▸ APH1B Q8WW43 1/20 0.36
▸ NCSTN Q92542 1/20 0.36
▸ APH1A Q96BI3 1/20 0.36
▸ PSENEN Q9NZ42 1/20 0.36
▸ PTGES O14684 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16058089 0.86 RARB (0.39) SLC22A12MAPTKDM4EMEN1KMT2A
SCHEMBL16057846 0.85 CCNB2 (0.45) BACE1MAPTKDM4EMEN1CRHBP
SCHEMBL16056843 0.80 CYP2C9 (0.44) MAPTKDM4EMEN1KMT2A
SCHEMBL16057906 0.77 KDM5A (0.38) MAPTKDM4EMEN1KMT2A
SCHEMBL16057060 0.77 RARB (0.46) MAPTKDM4EMEN1KMT2A
SCHEMBL16058925 0.76 CYP1A2 (0.40) KDM4E
SCHEMBL16057745 0.73 CYP2D6 (0.49) MAPTKDM4EKMT2A
SCHEMBL16058150 0.72 PDE10A (0.40) ACACBALOX5MAPTKDM4EKMT2A
SCHEMBL16057936 0.71 KIF11 (0.40) TOP2ABACE1MAPTKDM4EKMT2A
SCHEMBL5740381 0.71 TACR1 (0.54) TOP2ABACE1PPARDTACR1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 TOP2A 1892/4885BACE1 159/4885GPR119 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback